Document:

EX-10.17

 Exhibit 10.17 
 MANUFACTURING AND SUPPLY AGREEMENT 
 THIS AGREEMENT (“Agreement”)
is made and entered into this 23rd day of May 2006, (“Effective Date”) by and between Merck Eprova AG, a Swiss corporation, having a place of business at Im Laternenacker 5, 8200 Schaffhausen, Switzerland (“EPRO”) and
Spectrum Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 157 Technology Drive, Irvine, California, 92618, United States (“SPECTRUM”). EPRO and SPECTRUM may hereinafter each be referred to as a “Party”
or collectively as the “Parties”. Capitalized terms used in this Agreement shall have the meaning set forth herein or in the License Agreement (as defined below). 
 WITNESSETH: 
 WHEREAS, SPECTRUM is licensing certain technology from EPRO
(the “Technology”) pursuant to a License Agreement dated May 23, 2006 executed by the Parties herewith (the “License Agreement”); 
 WHEREAS, EPRO is engaged in the business of manufacturing drug substances and it has the expertise and appropriate government approvals necessary to manufacture the drug substance incorporating the
Technology; 
 WHEREAS, EPRO and SPECTRUM have agreed to the following terms and conditions, and desire to enter into this
Manufacturing and Supply Agreement (the “Agreement”); and 
 WHEREAS, it is the desire and intention of SPECTRUM that
EPRO use the Technology to manufacture or have manufactured the drug substance Calcium Levofolinate (hereinafter “Product”), upon the terms and conditions hereinafter set forth. 

NOW, THEREFORE, the Parties, in consideration of the mutual covenants and agreements contained in this Agreement, and for other good and
valuable consideration, the receipt and adequacy of which are hereby acknowledged, and with the Parties intending to be legally bound do hereby agree as follows: 
  

	Article 1	Product Manufacture 

 (a)
During the term of this Agreement, SPECTRUM shall from time to time, place orders with EPRO . EPRO shall process and deliver the Product pursuant to such orders, in compliance with the Specifications as defined in Exhibit A attached hereto.

 EPRO shall have the right to require SPECTRUM to pay 10% of the price for that amount of the Minimum Quantities of Product which have not
been ordered by SPECTRUM. 
 (b) EPRO shall manufacture and have ready for shipment the ordered quantities of the Product within
ninety (90) days from receipt of a written purchase order from SPECTRUM hereunder. SPECTRUM shall furnish EPRO with its three (3) year forecast on the Effective Date and every three (3) months with its rolling forecast for the
following twelve (12) month period for the Product, however, any such estimates shall not be binding or otherwise limit or obligate SPECTRUM in any way except for the first six (6) months which shall be binding and shall be referred to as
the “Minimum Quantities.” 

  
 - 1 -

 (c) From time to time during the term of this Agreement, the Parties by mutual consent, may
add to or modify the Specifications attached hereto as Exhibit A by reasonable advance written notice. EPRO will update its drug master file (DMF) every time the drug substance specifications are changed. 

(d) EPRO shall not actively manufacture the Product for any third party for the Field of Use in the Territory and shall cooperate in good
faith with Spectrum to insure that Product sold to any third party shall not be re-sold or used by that Party in the Field of Use in the Territory. 
 (e) SPECTRUM shall purchase its Product requirements exclusively from EPRO during the term of this Agreement. 
 (f) EPRO shall not manufacture or sell any product using the Technology or license its knowledge of the Technology to enable other manufacturers to make available the Product in the Field of Use in the
Territory. 
 (g) EPRO shall manufacture the Product at its facility located at Schaffhausen, Switzerland
(“EPRO’s Facility”), which facility will have to be inspected and approved by SPECTRUM prior to shipment of any commercial Product, and meets with all FDA requirements. EPRO will use commercially reasonable efforts to file a Drug
Master File (“DMF”) for the manufacture of the Product before November 1st, 2006 and will be responsible for all associated costs. EPRO hereby represents and warrants that EPRO’s Facility, including the real estate on which it is situated and all equipment located therein
is now, and shall be for the term of this Agreement, owned and operated solely by EPRO or an Affiliate thereof. EPRO, at its expense, shall furnish upon written request from SPECTRUM, the complete filing of the DMF directly to the United States Food
and Drug Administration (“FDA”) under confidentiality obligations prior to SPECTRUM’s submission to the FDA of its deficiency response associated with the New Drug Application (“NDA”) for the Product, and the “open
part” of the DMF to SPECTRUM. EPRO shall also furnish, at its expense, all available equivalent documentation to the regulatory authorities in Canada and Mexico to support future regulatory filings in those territories where SPECTRUM has
marketing rights, in addition to any other documents, as may be reasonably requested by SPECTRUM and are available at EPRO, related to the Drug Master File. 
 (h) After NDA-approval of a Licensed Product, EPRO shall be required to maintain an inventory of at least fifteen (15) kilograms of the Product, and will promptly manufacture said Product upon the
receipt of a purchase order. 
  

	Article 2	Prices 

 (a) SPECTRUM
shall pay to EPRO in full and complete consideration for the manufacture, control and delivery of the Product hereunder, the price as specified in Article 2(b) and (c) hereof (the “Price”). EPRO shall supply all materials necessary
for the manufacture and packaging of the Product. 
 (b) During the term of this Agreement, the Price of the Product shall be
USD 27 per gram calculated as anhydrous free acid from the Effective Date until December 31, 2009. 

  
 - 2 -

 (c) SPECTRUM shall pay to EPRO the actual Price of the Product delivered to SPECTRUM
hereunder. On January 1, 2010, and thereafter each January 1, the Price of the Product may be renegotiated by the mutual agreement of both Parties. SPECTRUM shall be able to obtain competitive prices and if SPECTRUM is able to obtain a
lower price from another manufacturer in a bonafide third party offer for Product in commercial quantities and similar quality (i.e Product should be acceptable by the health authorities and the alternative supplier shall give proof of its
commitment to file a respective DMF for the Territory), then SPECTRUM shall be able to terminate this Agreement and use the other manufacturer provided that EPRO shall have the opportunity to meet such competitive offer price in which case SPECTRUM
shall continue to purchase its total demand of Product from EPRO until the following January 1st. 
  

	Article 3	Raw Materials and Packaging 

 (a) All ingredients and raw materials used by EPRO for the manufacture of the Product shall conform to the set Specifications and must meet the requirements of the FDA for current Good Manufacturing
Practices (“cGMP”) compliance. 
 (b) EPRO will package the Product according to EPRO’s most recent packaging
guidelines, which are set forth in Exhibit B hereto, and label the Product in accordance with FDA’s and applicable labeling regulations, so that the Product is ready-to-ship to a third party toll manufacturer for finished good
production. 
 (c) EPRO agrees to inform SPECTRUM within fifteen (15) days of the result of any regulatory development or
major changes in specifications of the raw materials and/or of the Product that may materially affect the Product. EPRO shall notify SPECTRUM of and require written approval from SPECTRUM for changes as agreed in the Quality Agreement. 

(d) The capitalized terms in this Article 3 shall have the meaning set forth below: 

 

	 	a.	BATCH shall mean a specific quantity of Product comprising a number of units mutually agreed upon between SPECTRUM and EPRO, and that (a) is intended to have
uniform character and quality within specified limits, and (b) is produced according to a single manufacturing order during the same cycle of Production. 

 

	 	b.	Master Batch Record (MBR) shall mean the formal set of instructions for the Production of Product. The MBR will be developed and maintained in EPRO’s standard
format. 

  

	 	c.	Production or Product shall mean the manufacturing operation including compounding, filling, packaging, inspection, labeling, and testing of the Product by EPRO.

  

	Article 4	Delivery, Payment and Title to Product 

 (a) All Product shipments shall be delivered to SPECTRUM or a designated toll manufacturer, CIF nearest international airport from EPRO’s Facility and placed by EPRO into the custody of carriers
pursuant to SPECTRUM’s written directions. EPRO shall furnish to SPECTRUM sufficient information to verify shipment of the Product. 
  

  
 - 3 -

 (b) EPRO shall invoice SPECTRUM for the Product on the date such Product shipment is shipped
from EPRO’s Facility on instructions from SPECTRUM. Terms of payment shall be net forty-five (45) days from the date of such invoice. Late payments must bear ten (10) percent interests per annum. 

SPECTRUM shall bear the risk of loss or damage to any Product after the same shall have been delivered to the possession of either SPECTRUM, the toll
manufacturer or to SPECTRUM’s carrier pursuant to SPECTRUM’s instructions, except for loss or damage caused by the manufacturing, processing, packaging, or quality of the Product, in which case such loss or damage shall be borne solely by
EPRO. EPRO shall bear the risk of loss or damage to any Product ordered hereunder prior to the delivery of such Product to SPECTRUM, the toll manufacturer or to the carrier designated by SPECTRUM for transportation thereof. 

 

	Article 5	Inspection, Manufacturing Compliance, Acceptance of Product 

 (a) SPECTRUM may once per year, or more often if reasonably necessary, during normal business hours and with at least ten (10) days prior notice, visit EPRO’s facility to observe the manufacture
and packaging of the Product, and/or to audit the facility for quality and to collect samples of the Product. 
 (b) A
certificate of analysis for each Batch delivered shall set forth the items tested, Specifications, and test results and a re-test date. EPRO shall send, or cause to be sent, such certificates to SPECTRUM prior to the shipment of Product (unless
Product is shipped under quarantine). SPECTRUM shall test, or cause to be tested, for release for further manufacturing, each Batch of Product as meeting the Specifications within thirty (30) days after receipts by SPECTRUM. 

(c ) SPECTRUM’s payments for Product shipments received by SPECTRUM shall not constitute approval or acceptance of such Product. If
the Product is defective or does not conform to samples, descriptions or the Specifications attached hereto as Exhibits A and/or B, SPECTRUM is hereby granted the option to reject all shipped lots of the Product, accept all Batches, or
accept any Batchess thereof and reject the rest. EPRO shall reimburse SPECTRUM in full for those Products rejected and returned, and EPRO shall assume all costs of transportation and handling both ways. If not rejected within thirty (30) days,
the Product shall be deemed accepted. 
 (d) EPRO shall from time to time furnish to SPECTRUM upon reasonable written request,
without charge, pre-shipment samples of the Product that SPECTRUM needs for quality control, testing and evaluation. 
 (e) In
case, EPRO does not agree that the rejected Products are defective or the defectiveness of the Products has not been caused by EPRO, the Parties will appoint an independent third party expert whose results shall be final and binding. The costs for
such procedure and the handling of the defective Product shall be borne by the Party whose determination was in error. 
 (f)
Unless otherwise stated, EPRO is responsible for compliance with cGMP and any applicable United States, Canadian and Mexican Laws and any applicable local laws and regulations (“Regulations”) as they apply generally to production of drug
substances at the site of manufacturing. SPECTRUM shall be responsible for compliance with all Regulations as they apply to all other aspects of the use and sale of Product, which responsibility shall include, without limitation, all contact with
the FDA regarding the foregoing. 

  
 - 4 -

	Article 6	Warranties and Representations 

 (a) The Product manufactured, processed and packaged hereunder shall be manufactured, processed and packaged in conformity with cGMP’s and the Specifications set forth in Article 1, Exhibits A and
B of this Agreement. EPRO covenants, represents and warrants that the Product shall be produced in accordance with cGMP. EPRO covenants, represents and warrants that it has obtained (or will obtain prior to producing the Product), and will
remain in compliance with during the term of this Agreement, all permits, licenses and other authorizations which are required under federal, state and local laws, rules and regulations applicable to the production only of the Product.

 (b) All materials, ingredients, supplies and packaging materials utilized in the manufacture of Product sold hereunder shall
be merchantable, of good quality and fit for the purpose intended. 
 (c) EPRO has, and shall maintain during the term of this
Agreement, the capability to manufacture, package and deliver to SPECTRUM, under the terms of this Agreement, at least ten (10) kilograms of the Product per month, if ordered by SPECTRUM. The Parties may adjust the required quantity from time
to time. 
 (d) The execution of this Agreement and performance hereunder does not, and will not, abrogate, breach, or conflict
with any agreement, mortgage, pledge, or contract to which EPRO is a Party. 
  

	Article 7	Indemnities 

 EPRO shall
assume all responsibility for and shall defend, indemnify and hold SPECTRUM and its directors, members, officers, employees, agents, consultants, shareholders, affiliates, toll manufacturer, partners or advisors or those of its subsidiaries and/or
affiliates (“Representatives”) harmless from and against any and all liability, losses, expenses, damages, assessments and claims, causes of action, settlement costs, including reasonable attorney’s fees, or other liabilities of any
kind (collectively, “Damages”) arising out of, resulting from or attributable to 
 (a) defects relating to a
defective Product (defectiveness caused by EPRO); or 
 (b) material breach by EPRO of any term or provision of this Agreement;
or 
 (c) negligent act or omission by EPRO and its Representatives; provided, that this (a) shall not obligate EPRO to
indemnify SPECTRUM for any portion of Damages directly attributable to, and directly caused by, the negligence or omission of SPECTRUM and/or its Representatives. 

  
 - 5 -

 SPECTRUM shall assume all responsibility for and shall defend, indemnify and hold EPRO and
its Representatives harmless from and against any and all Damages arising out of, resulting from or attributable to: 
 (a) the
use, sale, offer to sell, transfer or import of Product after acceptance by SPECTRUM; or 
 (b) material breach by SPECTRUM of
any term or provision of this Agreement; or 
 (c) negligent act or omission by SPECTRUM and/or its Representatives; provided,
that this (a) shall not obligate SPECTRUM to indemnify EPRO for any portion of Damages directly attributable to, and directly caused by, the negligence or omission of EPRO and/or its Representatives. 

A party (the “Indemnitee”) which intends to claim indemnification under this Article 7 shall promptly notify the other party
(the “Indemnitor”) in writing of any action, claim or other matter in respect of which the Indemnitee or any of its Affiliates, or any of their respective directors, officers, employees, subcontractors, or agents, intend to claim such
indemnification; provided, however, that failure to provide such notice within a reasonable period of time shall not relieve the Indemnitor of any of its obligations hereunder except to the extent the Indemnitor is prejudiced by such failure. The
Indemnitee shall permit, and shall cause its Affiliates, and their respective directors, officers, employees, subcontractors and agents to permit, the Indemnitor, at its discretion, to settle any such action, claim or other matter, and the
Indemnitee agrees to the complete control of such defense or settlement by the Indemnitor. Notwithstanding the foregoing, the Indemnitor shall not enter into any settlement that would adversely affect the Indemnitee’s rights hereunder, or
impose any obligations on the Indemnitee in addition to those set forth herein, in order for it to exercise such rights, without Indemnitee’s prior written consent, which shall not be unreasonably withheld or delayed. No such action, claim or
other matter shall be settled without the prior written consent of the Indemnitor, which shall not be unreasonably withheld or delayed. The Indemnitee, its Affiliates, and their respective directors, officers, employees, subcontractors and agents
shall fully cooperate with the Indemnitor and its legal representatives in the investigation and defense of any action, claim or other matter covered by the indemnification obligations of this Article 7. The Indemnitee shall have the right, but not
the obligation, to be represented in such defense by counsel of its own selection and at its own expense. 
 The indemnification
obligations set forth in this Article shall survive the expiration or termination of this Agreement. 
  

	Article 8	Insurance 

 (a) EPRO shall
procure and maintain, during the term of this Agreement and for a period one (1) year beyond the expiration date of Product, comprehensive general liability insurance in the amount of $2,000,000 per occurrence and annual aggregate combined
single limit for bodily injury and property damage liability and products liability insurance in the amount of $10,000,000 per occurrence and annual aggregate combined single limit for bodily injury and property damage liability. All of such
insurance coverage shall be maintained with an insurance company or companies having an A.M. Best rating of A – VII or better. EPRO promptly shall deliver, upon written request by SPECTRUM, a certificate of EPRO’S insurance evidencing such
coverage. 
 (b) SPECTRUM shall procure and maintain, during the term of this Agreement and for a period one (1) year
beyond the expiration date of Product, comprehensive general liability insurance in the amount of $2,000,000 per occurrence and annual aggregate combined single limit for bodily injury and property damage liability and products liability insurance
in the amount of $10,000,000 per occurrence and annual aggregate combined single limit for bodily injury and property damage liability. All of such insurance coverage shall be maintained with an insurance company or companies having an A.M. Best
rating of A – VII or better. EPRO shall be named as an additional insured on the SPECTRUM insurance and SPECTRUM promptly shall deliver, upon written request by EPRO, a certificate of SPECTRUM insurance and endorsement of additional insured to
EPRO evidencing such coverage. 

  
 - 6 -

	Article 9	Intellectual Property Rights 

 Rights to the intellectual property in the Product and the underlying Technology shall be as set forth in the License Agreement. 

 

	Article 10	Assignment 

 This Agreement shall be
binding upon and inure to the benefit of the successors or permitted assigns of each of the Parties and may not be assigned or transferred by either Party without the prior written consent of the other, which consent will not be unreasonably
withheld or delayed, except that no consent shall be required in the case of a transfer to a wholly-owned subsidiary or transaction with a third party involving the merger, consolidation or sale of substantially all of the assets of the Party
seeking such assignment or transfer and such transaction relates to the business covered by this Agreement and the resulting entity assumes all the obligations under this Agreement. No assignment shall relieve any Party of responsibility for the
performance of its obligations hereunder. 
  

	Article 11	Confidentiality 

 The Parties shall be
bound to the same confidentiality provisions as set forth in Article III of the License Agreement and set forth in the Mutual Confidentiality Agreement dated November 1, 2005. 

 

	Article 12	Term and Termination 

 (a)
Subject to Article 2(c) above, this Agreement is effective on the Effective Date and shall remain in full force and effect for as long as SPECTRUM is required to pay EPRO a royalty payment under Article V(A)(2)(a), (b), (c) or (d) under
the License Agreement. This Agreement may be renewed only upon written agreement of the Parties. 
 (b) Either Party may
terminate this Agreement in the event of a material breach by the other Party of this Agreement that is not cured within sixty (60) days from notice of such breach by the non-breaching Party. 

(c) Termination, expiration, cancellation or abandonment of this Agreement through any means or for any reason, except as set forth in
Articles 12(a) or 12(b), shall be without prejudice to the rights and remedies of either Party with respect to any antecedent breach of any of the provisions of this Agreement. The provisions of Articles 6, 7, 8, 9, 11, 12, 13, 15 and 16 hereof
shall survive expiration or termination of this Agreement. 

  
 - 7 -

	Article 13	Notices 

 All notices
under this Agreement shall be in writing and shall be either mailed, return receipt requested, to the addresses set forth above or transmitted by facsimile, with confirmation of transmission, to the facsimile number listed below: 

 

			
	For EPRO:	  	Merck Eprova AG
		  	Im Laternenacker 5
		  	8200 Schaffhausen
		  	Switzerland
		  	Attention: Martin Ulmann
		  	Fax: ++41 (0)52 630 7255
		
	For SPECTRUM:	  	Spectrum Pharmaceuticals, Inc.
		  	157 Technology Drive
		  	Irvine, CA 92618
		  	U.S.A.
		  	Attention: V.P., General Counsel
		  	Fax: 1 (949) 788-6706

  

	Article 14	Scope of Agreement 

 This
Agreement shall constitute the entire agreement between the Parties pertaining to the subject matter thereof. Neither Party is authorized to make any representation, warranty, or promise on behalf of the other Party. No change, termination or
attempted waiver of any of the provisions hereof shall be binding upon a Party unless signed by a duly authorized officer of the Party. Neither Party shall represent that it has power to bind the other Party or to assume or to create any obligation
or responsibility, expressed or implied, on behalf of the other Party. 
  

	Article 15	Dispute Resolution 

 Any
and all disputes under the Agreement shall be settled in accordance with the dispute resolution procedure set forth in Article XIII of the License Agreement. 
  

	Article 16	Applicable Law 

 This
Agreement shall be construed in accordance with Article XI of the License Agreement. 
  

	Article 17	Severability 

 If any
portion of this Agreement shall be in violation of any applicable law, rule or regulation, such portion shall be inoperative, but the remainder of the Agreement shall remain valid and continue to bind the Parties. 

  
 - 8 -

	Article 18	Independent Contractors 

The Parties are independent contractors and engage in the operation of their own respective businesses, and neither SPECTRUM nor EPRO
shall be considered an employee, agent or joint venture partner of the other for any purpose whatsoever. Neither SPECTRUM nor EPRO shall have any authority to enter into any contracts or assume any obligations for the other or to make any warranties
or representations on behalf of the other. 
  

	Article 19	Headings, Interpretation 

The headings used in this Agreement are for convenience only and are not part of this Agreement. 

SIGNATURE PAGE FOLLOWS 

  
 - 9 -

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
respective duly authorized representatives on the day and year first above written. 
 Merck Eprova AG 

 

			
	By:	 	 /s/ Martin Ulmann

		 	Martin Ulmann
	Title:	 	General Manager
	Date:	 	June 1, 2006
		
	By:	 	 /s/ Thomas Suter

		 	Thomas Suter
	Title:	 	Chief Financial Officer
	Date:	 	June 1, 2006

 Spectrum Pharmaceuticals, Inc. 
  

			
	By:	 	 /s/ Rajesh C. Shrotriya

		 	Rajesh C. Shrotriya, M.D.
	Title:	 	Chairman, CEO and President
	Date:	 	May 19, 2006

  
 - 10 -

 EXHIBIT A 
 SPECIFICATIONS 
 CALCIUM LEVOFOLINATE (L-CALCIUM FOLINATE) 

SPECIFICATIONS for Purchase by SPECTRUM. 
  

					
	Appearance / Solubility	  	  A white to light yellow, crystalline powder. Slightly soluble in water, practically insoluble in acetone and
  alcohol.
		
	Identification	  	
		
	 •    IR-spectrum
	  	  complies with that of the reference standard
		
	 •    HPLC-retention time
	  	  complies with that of the reference standard
		
	 •    Calcium
	  	  positive
		
	Appearance of solution	  	  clear, absorbance at 420 nm not more than 1.0 AU measured in a 4 cm cuvette.
		
		  	  (This corresponds to an absorbance of 0.25 measured in a 1 cm cuvette)
		
	pH	  	  7.5 to 8.5
		
	Optical rotation	  	 •    10° to -15° on anhydrous and solvent free basis

			
	Residual solvent	  	 •    acetone:
	  	not more than 0.5%
			
		  	 •    ethanol:
	  	not more than 0.5%
			
		  	 •    methanol:
	  	not more than 0.2%
			
		  	 •    2-propanol:
	  	not more than 0.5%

					
	Related substances	  	  Individual related compounds (% w/w)
			
		  	 •    folic acid:
	  	not more than 0.15%
			
		  	 •    formylfolic acid:
	  	not more than 0.1%
			
		  	 •    p-aminobenzoylglutamic acid:
	  	not more than 0.4%
			
		  	 •    formyltetrahydropteroic acid:
	  	not more than 0.4%
			
		  	 •    RC (8) *:
	  	not more than 0.3%
			
		  	 •    RC (9):
	  	not more than 0.1%
			
		  	 •    RC (10) *:
	  	not more than 0.3%
			
		  	 •    individual other related comp.:
	  	not more than 0.2%
			
		  	  sum related compounds:	  	not more than 1.5%
		
	D-isomer (impurity H)	  	  not more than 0.5%
		
	Chloride	  	  not more than 0.5%
		
	Heavy metals	  	  not more than 20 ppm
		
	Platinum	  	  not more than 10 ppm
		
	Water	  	  12.0 to 17.0%
		
	Assay	  	
		
	 •    Folinate
	  	  not less than 97.0% and not more than 102.0% calculated on the anhydrous and solvent free basis (actual   USP-reference
standard)
		
	 •    Calcium
	  	  7.54 to 8.14% on anhydrous and solvent free basis
		
	Bacterial endotoxins	  	  not more than 0.2 EU / mg
		
	Total microbial count	  	  not more than 50 CFU/g
		
	Yeast and mould	  	  not more than 50 CFU/g
		
	Absence of pathogens	  	  absence of E. Coli in 10 g
		  	  absence of Salmonella in 10 g
	 	  	  absence of St. aureus in 10 g
		  	  absence of Ps. aeruginosa in 10 g

					
	Particle size	  	  90% less than 190 μm
		  	  50% less than 100 μm

  

	*	The impurity limits must meet ICH guidelines Q3AR. EPRO will perform identification studies for the two (2) impurities for inclusion in their DMF.

 EXHIBIT B 
 PACKAGING GUIDELINES 
 Bags: 

 

	 	•	 	 Low-density polyethylene (LDPE) bag 

 Supplier: Plasti-Pack, Zürich, Switzerland 
  

	 	•	 	 Low-density polyethylene (LDPE)/ aluminium composite foil bag 

Supplier: VTT AG Reinach, Switzerland 
 Drum: 
 Fibre drum of impregnated cardboard, spirally wound up, which acts as steam barrier
(bottom and jacket). Lid made of hardboard, with galvanised closing ring. 
 Supplier:     IZag Zofingen, Zofingen,
Switzerland 
 Procedure 
 Bulk
powder is filled into the first bag (polyethylene). Then the bag is closed, labelled with product name, batch no. and weight. 
 The second bag
(polyethylene / aluminium composite) is heat-sealed, labelled and placed into the fibre drum. The drum is also labelled and secured with an individually numbered seal. 
 Storage temperature: 2o to 8o C 

 EXHIBIT C 
 EPRO Bank Account 
  

			
	Receiving party:	  	Merck Eprova AG
	Account# (USD):	  	230-EW103618.0
	IBAN:	  	CH48 0023 0230 EW10 3618 0
	SWIFT-code:	  	UBSWCHZH80AThird Supplemental Indenture

 EXHIBIT 4.1 
 Southern Copper Corporation 
 as Issuer 

and 

Wells Fargo Bank, National Association, 
 as Trustee 
  

 
 THIRD
SUPPLEMENTAL INDENTURE 
 Dated as of November 8, 2012 

to 

INDENTURE 

Dated as of April 16, 2010 
  

 
 3.500% Notes
due 2022 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	
	ARTICLE 1.	  
	
	DEFINITIONS	  
			
	 Section 1.1.
	  	 Definition of Terms
	  	 	2	  
	
	ARTICLE 2.	  
	
	GENERAL TERMS AND CONDITIONS OF THE NOTES	  
			
	 Section 2.1.
	  	 Designation and Principal Amount
	  	 	7	  
	 Section 2.2.
	  	 Maturity
	  	 	7	  
	 Section 2.3.
	  	 Further Issues
	  	 	7	  
	 Section 2.4.
	  	 Form of Payment
	  	 	7	  
	 Section 2.5.
	  	 Global Securities
	  	 	7	  
	 Section 2.6.
	  	 Interest
	  	 	7	  
	 Section 2.7.
	  	 Authorized Denominations
	  	 	7	  
	 Section 2.8.
	  	 Redemption
	  	 	8	  
	 Section 2.9.
	  	 Limitation on Liens
	  	 	8	  
	 Section 2.10.
	  	 Limitation on Sale and Leaseback Transactions
	  	 	9	  
	 Section 2.11.
	  	 Repurchase at Option of Holders Upon Change of Control Triggering Event
	  	 	10	  
	 Section 2.12.
	  	 Merger, Consolidation and Sale of Assets
	  	 	11	  
	 Section 2.13.
	  	 Events of Default
	  	 	12	  
	 Section 2.14.
	  	 Appointment of Agents
	  	 	13	  
	 Section 2.15.
	  	 Defeasance upon Deposit of Moneys or U.S. Government Obligations
	  	 	13	  
	 Section 2.16.
	  	 Amendments
	  	 	14	  
	
	ARTICLE 3.	  
	
	FORM OF NOTES	  
			
	 Section 3.1.
	  	 Form of Notes
	  	 	14	  
	
	ARTICLE 4.	  
	
	ORIGINAL ISSUE OF NOTES	  
			
	 Section 4.1.
	  	 Original Issue of Notes
	  	 	14	  

  
 i 

							
	ARTICLE 5.	  
	
	MISCELLANEOUS	  
			
	 Section 5.1.
	  	 Ratification of Indenture
	  	 	14	  
	 Section 5.2.
	  	 Trustee Not Responsible for Recitals
	  	 	15	  
	 Section 5.3.
	  	 Governing Law
	  	 	15	  
	 Section 5.4.
	  	 Severability
	  	 	15	  
	 Section 5.5.
	  	 Counterparts
	  	 	15	  
		
	 EXHIBIT A – Form of Notes
	  	 	A-1	  

  
 ii 

 THIRD SUPPLEMENTAL INDENTURE, dated as of November 8, 2012 (this “Third
Supplemental Indenture”), between Southern Copper Corporation, a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), and Wells Fargo Bank, National Association, a national banking
association, as trustee (the “Trustee”). 
 WHEREAS, the Company and the Trustee executed and delivered the
indenture, dated as of April 16, 2010 (the “Base Indenture”, as supplemented by a First Supplemental Indenture and a Second Supplemental Indenture, in each case dated as of April 16, 2010, and a Fourth Supplemental Indenture,
dated as of November 8, 2012, and, together with this Third Supplemental Indenture, the “Indenture”), to provide for the issuance of the Company’s debt securities (the “Securities”), to be issued in one or more series;

 WHEREAS, pursuant to the terms of the Base Indenture, the Company desires to provide for the establishment of a new
series of its notes under the Base Indenture to be known as its “3.500% Notes due 2022” (the “Notes”), the form and substance and the terms, provisions and conditions thereof to be set forth as provided in the Base Indenture and
this Third Supplemental Indenture; 
 WHEREAS, the Board of Directors of the Company pursuant to resolutions duly adopted
on October 18, 2012, have duly authorized the issuance of the Notes, and has authorized the proper officers of the Company to execute any and all appropriate documents necessary or appropriate to effect each such issuance; 

WHEREAS, this Third Supplemental Indenture is being entered into pursuant to the provisions of Section 14.01 of the Base
Indenture; 
 WHEREAS, the Company has requested that the Trustee execute and deliver this Third Supplemental Indenture;
and 
 WHEREAS, all things necessary to make this Third Supplemental Indenture a valid and legally binding agreement of
the Company, in accordance with its terms, and to make the Notes, when executed by the Company and authenticated and delivered by the Trustee, the valid and legally binding obligations of the Company, have been performed, and the execution and
delivery of this Third Supplemental Indenture has been duly authorized in all respects; 
 NOW THEREFORE, in
consideration of the premises and the purchase and acceptance of the Notes by the Holders thereof, and for the purpose of setting forth, as provided in the Base Indenture, the forms and terms of the Notes, the Company covenants and agrees, with the
Trustee, as follows: 

  
 1 

 ARTICLE 1. 
 DEFINITIONS 
 Section 1.1. Definition of Terms. Unless
the context otherwise requires: 
 (a) each term defined in the Base Indenture has the same meaning when used in this Third
Supplemental Indenture except as otherwise defined in this Third Supplemental Indenture; 
 (b) the singular includes the plural
and vice versa; and 
 (c) headings are for convenience of reference only and do not affect interpretation. 

(d) a reference to a Section or Article is to a Section or Article of this Third Supplemental Indenture unless otherwise indicated.

 (e) The following terms have the meanings given to them in this Section 1.1(e): 

(i) “Affiliate” means, with respect to any specified Person, any other Person directly or indirectly controlling
or controlled by or under direct or indirect common control with such specified Person. For purposes of this definition, “control,” when used with respect to any specified Person, means the power to direct the management and policies of
such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise. 
 (ii) “Attributable Value” in respect of a Sale and Leaseback Transaction means, as to any particular lease under which the Company or any Subsidiary is at any time liable as lessee and any date
as of which the amount thereof is to be determined, the total net obligations of the lessee for rental payments (excluding, however, any amounts required to be paid by such lessee, whether or not designated as rent or additional rent, on account of
maintenance and repairs, services, insurance, taxes, assessments, water rates or similar charges and any amounts required to be paid by such lessee thereunder contingent upon monetary inflation or the amount of sales, maintenance and repairs,
insurance, taxes, assessments, water rates or similar charges) during the remaining term of the lease (including any period for which such lease has been extended or may, at the option of the lessor, be extended) discounted from the respective due
dates thereof to such date at a rate per annum equivalent to the interest rate inherent in such lease (as determined in good faith by the Company in accordance with generally accepted financial practice). 

(iii) “Change of Control,” at any date, means the failure of Mr. German Larrea Mota-Velasco and his
immediate family members, including his spouse, parents, siblings, and lineal descendents, estates and heirs, or any trust or other investment vehicle for the primary benefit of any of the foregoing, to possess, directly or indirectly, whether
through ownership of Voting Stock, contract or otherwise, the power to elect or designate for election the majority of the board of directors of the Company or to direct or cause the direction of the management or policies of the Company.

  
 2 

 (iv) “Change of Control Offer” shall have the meaning assigned to
it in Section 2.11(a). 
 (v) “Change of Control Purchase Price” shall have the meaning assigned
to it in Section 2.11(a). 
 (vi) “Change of Control Triggering Event” means the occurrence of
both a Change of Control and a Rating Decline. 
 (vii) “Commission” means the Securities and Exchange
Commission, as from time to time constituted, created under the Securities Exchange Act of 1934, as amended, or, if at any time after the execution of this Indenture such Commission is not existing and performing the duties now assigned to it under
the Trust Indenture Act, then the body performing such duties at such time. 
 (viii) “Comparable Treasury
Issue” means the United States Treasury security selected by the Independent Investment Banker as having a maturity comparable to the remaining term (“remaining life”) of the Notes that would be utilized, at the time of selection and
in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of such series of Notes. 

(ix) “Comparable Treasury Price” means, with respect to any redemption date, (i) the average of five
Reference Treasury Dealer Quotations for such redemption date, after excluding the highest and lowest Reference Treasury Dealer Quotations, or (ii) if the Independent Investment Banker is unable to obtain at least five such Reference Treasury
Dealer Quotations, the average of all Reference Treasury Dealer Quotations obtained by the Independent Investment Banker. 
 (x) “Consolidated Net Tangible Assets” means the total of all assets appearing on a consolidated balance sheet of the Company and its Subsidiaries, net of all applicable reserves and deductions,
but excluding goodwill, trade names, trademarks, patents, unamortized debt discount and all other like intangible assets, less the aggregate of the current liabilities of the Company and its Subsidiaries appearing on such balance sheet as determined
in accordance with U.S. GAAP. 
 (xi) “Debt” means indebtedness for borrowed money. 

(xii) “DTC” shall have the meaning assigned to it in Section 2.5. 

(xiii) “Event of Default” shall have the meaning assigned to it in Section 2.12. 

(xiv) “Fitch” means Fitch Ratings, Ltd. or any successor to the rating agency business thereof. 

  
 3 

 (xv) “Guarantee” means any obligation, contingent or otherwise, of
any Person directly or indirectly guaranteeing any Indebtedness of any other Person, direct or indirect, contingent or otherwise, or entered into for the purpose of assuring in any other manner the obligee of such Indebtedness of the payment thereof
or to protect such obligee against loss in respect thereof (in whole or in part); provided, however, that the term “Guarantee” shall not include endorsements for collection or deposit in the ordinary course of business. The
term “Guarantee” used as a verb has a corresponding meaning. The term “Guarantee” shall not apply to a guarantee of intercompany indebtedness among the Company and the Subsidiaries or among the Subsidiaries. 

(xvi) “Incurrence Time” shall have the meaning assigned to it in Section 2.9(b). 

(xvii) “Indebtedness” means, with respect to any person (without duplication): 

 

	 	(A)	any obligation of such Person (a) for borrowed money, under any reimbursement obligation relating to a letter of credit (other than letters of credit payable to
suppliers in the ordinary course of business), under any reimbursement obligation relating to a financial bond or under any reimbursement obligation relating to a similar instrument or agreement, (b) for the payment of money relating to any
obligations under any capital lease of real or personal property, or (c) under any agreement or instrument in respect of an interest rate or currency swap, exchange or hedging transaction or other financial derivatives transaction (other than
(x) any such agreements or instruments directly related to Indebtedness otherwise incurred in compliance with the Indenture and (y) any such agreements as are entered into in the ordinary course of business and are not for speculative
purposes or the obtaining of credit); and 

  

	 	(B)	any amendment, supplement, modification, deferral, renewal, extension or refunding of any liability of the types referred to in clause (1) above. For the purpose
of determining any particular amount of Indebtedness under this definition, Guarantees of (or obligations with respect to letters of credit) Indebtedness otherwise included in the determination of such amount shall not be included.

 (xviii) “Independent Investment Banker” means one of the Reference Treasury Dealers
appointed by the Company from time to time to act as the “Independent Investment Banker.” 

  
 4 

 (xix) “Lien” means any mortgage, pledge, security interest or
lien. 
 (xx) “Moody’s” means Moody’s Investors Service, Inc. or any successor to the rating
agency business thereof. 
 (xxi) “Person” means any individual, corporation, partnership, joint
venture, association, joint-stock company, trust, unincorporated organization, limited liability company or government or other entity. 
 (xxii) “Rating Agencies” means Moody’s, S&P and Fitch. 
 (xxiii) “Rating Decline” means if on, or within 90 days after, the earlier of the date of public notice of the occurrence of a Change of Control or of the intention of the Company to effect a
Change of Control (which period shall be extended so long as the rating of the Notes is under publicly announced consideration for possible downgrade by any of the Rating Agencies), the rating of the Notes of the applicable series by at least one of
the Rating Agencies shall be decreased by one or more gradations (including gradations within categories as well as between rating categories). 
 (xxiv) “Reference Treasury Dealer” means any one of HSBC Securities (USA) Inc., Morgan Stanley & Co. LLC, Credit Suisse Securities (USA) LLC, and Merrill Lynch, Pierce,
Fenner & Smith Incorporated and their respective successors and two other nationally recognized investment banking firm that is a Primary Treasury Dealer (as defined below) selected from time to time by the Company; provided,
however, that if any of the foregoing shall cease to be a primary US Government securities dealer in New York City (a “Primary Treasury Dealer”), the Company shall substitute therefor another nationally recognized investment banking
firm that is a Primary Treasury Dealer. 
 (xxv) “Reference Treasury Dealer Quotation” means, with
respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its
principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third business day preceding that redemption date. 

(xxvi) “Remaining Scheduled Payments” means, with respect to each note to be redeemed, the remaining scheduled
payments of the principal thereof and interest thereon that would be due after the related redemption date but for such redemption; provided, however, that, if that redemption date is not an interest payment date with respect to such
Notes, the amount of the next succeeding scheduled interest payment thereon will be reduced by the amount of interest accrued thereon to that redemption date. 
 (xxvii) “S&P” means Standard & Poor’s Ratings Services or any successor to the rating agency business thereof. 

(xxviii) “Sale and Leaseback Transaction” means any transaction or series of related transactions pursuant to
which the Company or any Subsidiary sells or transfers 

  
 5 

 
any property to any Person with the intention of taking back a lease of such property pursuant to which the rental payments are calculated to amortize the purchase price of such property
substantially over the useful life thereof and such property is in fact so leased. 
 (xxix) “Significant
Subsidiary” means a Subsidiary of the Company which would be a “significant subsidiary” within the meaning of Rule 1-02 under Regulation S-X promulgated by the Commission as in effect on the date of the Indenture, assuming the Company
is the registrant referred to in such definition. 
 (xxx) “Specified Property” means any mineral
property (other than inventory or receivables), concentrator, smelter, refinery or rod plant of the Company or any Subsidiary and any capital stock or Indebtedness of any Subsidiary directly owning any such property, concentrator, smelter, refinery
or rod plant. This term excludes any mineral property, concentrator, smelter or refinery or rod plant of the Company or any Subsidiary that in the good faith opinion of the Company’s board of directors is not materially important to the total
business conducted by the Company and its Subsidiaries, taken as a whole. 
 (xxxi) “Subsidiary” means
any corporation or other business entity of which the Company owns or controls (either directly or through one or more other Subsidiaries) more than 50% of the issued share capital or other ownership interests, in each case having ordinary voting
power to elect or appoint directors, managers or trustees of such corporation or other business entity (whether or not capital stock or other ownership interests or any other class or classes shall or might have voting power upon the occurrence of
any contingency). For the avoidance of doubt, SPCC Peru Branch shall not be considered a Subsidiary of the Company. 
 (xxxii) “Treasury Rate” means, with respect to any redemption date, the rate per annum equal to the semi-annual equivalent yield to maturity (computed as of the third business day immediately
preceding that redemption date) of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for that redemption date. 

(xxxiii) “U.S. GAAP” with respect to any computations required or permitted hereunder, means generally accepted
accounting principles in effect in the United States as in effect from time to time; provided, however if the Company is required by the Commission to adopt (or is permitted to adopt and so adopts) a different accounting framework, including but not
limited to the International Financial Reporting Standards, “GAAP” shall mean such new accounting framework as in effect from time to time, including, without limitation, in each case, those accounting principles set forth in the opinions
and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as
approved by a significant segment of the accounting profession. 
 (xxxiv) “Voting Stock” means capital
stock issued by a corporation, or equivalent interests in any other Person, the holders of which are ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons performing similar functions) of such
Person, even if the right to vote has been suspended by the happening of such a contingency. 

  
 6 

 ARTICLE 2. 
 GENERAL TERMS AND CONDITIONS OF THE NOTES 
 Section 2.1.
Designation and Principal Amount. There is hereby authorized and established a new series of Securities under the Base Indenture, designated as the “3.500% Notes due 2022”, which is not limited in aggregate principal amount. The
initial aggregate principal amount of the Notes to be issued under this Third Supplemental Indenture shall be limited to $300,000,000. Any additional amounts of such series to be issued shall be set forth in a Company Order. 

Section 2.2. Maturity. The stated maturity of principal for the Notes will be November 8, 2022. 

Section 2.3. Further Issues. The Company may from time to time, without the consent of the Holders of the Notes, issue
additional notes of such series. Any such additional notes will have the same ranking, interest rate, maturity date and other terms as the Notes. Any such additional notes, together with the Notes herein provided for, will constitute a single series
of Securities under the Indenture. 
 Section 2.4. Form of Payment. Principal of, premium, if any, and interest on
the Notes shall be payable in U.S. dollars. 
 Section 2.5. Global Securities. Upon the original issuance, the Notes
will be represented by one or more Global Securities. The Company will issue the Notes in denominations of $2,000 and in integral multiples of $1,000 in excess thereof and will deposit the Global Securities with the Trustee as custodian for The
Depository Trust Company (“DTC”), in New York, New York, and register the Global Securities in the name of DTC or its nominee. 
 Section 2.6. Interest. The Notes will bear interest (computed on the basis of a 360-day year consisting of twelve 30-day months) from November 8, 2012 at the rate of 3.500% per
annum, payable semiannually in arrears; interest payable on each interest payment date will include interest accrued from November 8, 2012, or from the most recent interest payment date to which interest has been paid or duly provided for; the
interest payment dates on which such interest shall be payable are May 8 and November 8 of each year, commencing on May 8, 2013; and the record date for the interest payable on any interest payment date is the close of business on
April 20 or October 20, as the case may be, next preceding the relevant Interest Payment Date. 
 Section 2.7.
Authorized Denominations. The Notes shall be issuable in denominations of $2,000 and in integral multiples of $1,000 in excess thereof. 

  
 7 

 Section 2.8. Redemption. The Notes are subject to redemption at the option of
the Company as set forth in the forms of Note attached hereto as Exhibit A. 
 Section 2.9. Limitation on Liens

 (a) The Company will not, nor will it permit any Subsidiary to, issue, assume or suffer to exist any Indebtedness or
Guarantee, if such Indebtedness or Guarantee is secured by a Lien upon any Specified Property, unless, concurrently with the issuance or assumption of such Indebtedness or Guarantee or the creation of such Lien, the Notes (together with, at the
Company’s option, any other indebtedness of or guarantee by the Company or its Subsidiaries then existing or thereafter created which is not subordinated to the Notes) shall be secured equally and ratably with (or at the Company’s option
prior to) such Indebtedness or Guarantee for so long as such Indebtedness or Guarantee is so secured; provided, however, that the foregoing restriction shall not apply to: 

(i) any Lien on (a) any Specified Property acquired, constructed, developed, extended or improved by the Company or
any Subsidiary (singly or together with other Persons) after the date of the Indenture or any property reasonably incidental to the use or operation of such Specified Property (including any real property on which such Specified Property is
located), or (b) any shares or other ownership interest in, or any Indebtedness of, any Person which holds, owns or is entitled to such property, products, revenue or profits, provided that in the case of both clause (a) and
(b) above, such Lien is created, incurred or assumed (x) during the period such Specified Property was being constructed, developed, extended or improved, or (y) contemporaneously with, or within 360 days after, such acquisition or
the completion of such construction, development, extension or improvement in order to secure or provide for the payment of all or any part of the purchase price or other consideration of such Specified Property or the other costs of such
acquisition, construction, development, extension or improvement (including costs such as escalation, interest during construction and financing and refinancing costs); 

(ii) any Lien on any Specified Property existing at the time of acquisition thereof and which (a) is not created as a
result of or in connection with or in anticipation of such acquisition and (b) does not attach to any other Specified Property other than the Specified Property so acquired; 

(iii) any Lien on any Specified Property acquired from a Person that is merged with or into the Company or any Subsidiary
or any Lien existing on Specified Property of any Person at the time such Person becomes a Subsidiary, in either such case which (a) is not created as a result of or in connection with or in anticipation of any such transaction and
(b) does not attach to any other Specified Property other than the Specified Property so acquired; 
 (iv)
any Lien which secures Indebtedness or a Guarantee owing by a Subsidiary to the Company or any other Subsidiary; 

  
 8 

 (v) any Liens on any Specified Property in favor of the government of the
United States, Mexico or Peru or of any other country or any political subdivision thereof, to secure payments pursuant to any contract with such government or to any statute to which the Company or any of its Subsidiaries is subject; 

(vi) any Lien existing on the date of this Third Supplemental Indenture; or 

(vii) any extension, renewal or replacement (or successive extensions, renewals or replacements) in whole or in part, of
any Lien referred to in the foregoing clauses (i) through (vi) inclusive; provided that the principal amount of Indebtedness or Guarantee secured thereby shall not exceed the principal amount of Indebtedness or Guarantee so secured
at the time of such extension, renewal or replacement plus an amount necessary to pay any fees and expenses, including premiums and defeasanse costs related to such transaction, and that such extension, renewal or replacement shall be limited to all
or a part of the property which secured the Lien so extended, renewed or replaced (plus improvements on such property). 
 (b)
Notwithstanding the foregoing, the Company or any Subsidiary may issue or assume Indebtedness or a Guarantee secured by a Lien which would otherwise be prohibited under the provisions of the Indenture described in this section or enter into Sale and
Leaseback Transactions that would otherwise be prohibited by the provisions of the Indenture described in Section 2.10, provided that the amount of such Indebtedness or Guarantee or the Attributable Value of such Sale and Leaseback
Transaction, as the case may be, together with the aggregate amount (without duplication) of (i) Indebtedness or Guarantees outstanding at such time that were previously incurred pursuant to this paragraph by the Company and its Subsidiaries,
plus (ii) the Attributable Value of all such Sale and Leaseback Transactions of the Company and its Subsidiaries outstanding at such time that were previously incurred pursuant to the provisions of the Indenture described in Section 2.10
shall not exceed 20% of Consolidated Net Tangible Assets at the time any such Indebtedness or Guarantee is issued or assumed by the Company or any Subsidiary or at the time any such Sale and Leaseback Transaction is entered into. 

(c) For the avoidance of doubt, the sale or other transfer of (i) any minerals in place for a period of time until, or in an amount
such that the purchaser will realize therefrom a specified amount of money (however determined) or a specified amount of such minerals or (ii) any other interest in property of the character commonly referred to as a “production
payment,” shall not constitute the incurrence of Indebtedness or a Guarantee secured by a Lien. 
 Section 2.10.
Limitation on Sale and Leaseback Transactions. 
 (a) Neither the Company nor any Subsidiary may enter into any Sale and
Leaseback Transaction with respect to any Specified Property, unless either (i) the Company or such Subsidiary would be entitled pursuant to the provisions of the Indenture described above under Section 2.9 to issue or assume Indebtedness
or a Guarantee (in an amount equal to the Attributable Value with respect to such Sale and Leaseback Transactions) secured by a Lien on such Specified Property without equally and ratably securing the Notes of such series; (ii) within 360 days
of such Sale and Leaseback Transaction, the Company or such Subsidiary applies or 

  
 9 

 
causes to be applied, in the case of a sale or transfer for cash, an amount equal to 85% of the net proceeds thereof and, in the case of a sale or transfer otherwise than for cash, an amount
equal to the fair market value (as determined in good faith by the board of directors of the Company) of the Specified Property so leased to: (A) to the retirement, within 360 days after the effective date of such Sale and Leaseback
Transaction, of (x) Indebtedness of the Company ranking at least pari passu in right of payment with the Notes of such series or (y) Indebtedness of any Subsidiary of the Company, in each case owing to a Person other than the
Company or any Affiliate of the Company, or (B) to the acquisition, purchase, construction, development, extension or improvement of any property or assets of the Company or any Subsidiary used or to be used by or for the benefit of the Company
or any Subsidiary in the ordinary course of business; or (iii) the Company or such Subsidiary equally and ratably secures the Notes of such series as described in Section 2.9. 

(b) The restrictions set forth in paragraph (a) above shall not apply to any transactions providing for a lease for a term of less
than three years. 
 Section 2.11. Repurchase at Option of Holders Upon Change of Control Triggering Event.

 (a) Upon the occurrence of a Change of Control Triggering Event, each Holder of Notes will have the right to require the
Company to repurchase all or any part of such Holder’s Notes pursuant to the offer described below (the “Change of Control Offer”) at a purchase price (the “Change of Control Purchase Price”) equal to 101% of the principal
amount thereof, plus accrued and unpaid interest, if any, to the purchase date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date). 

(b) Within 30 days following any Change of Control Triggering Event, the Company shall send, by first-class mail, with a copy to the
Trustee, to each Holder of Notes, at such Holder’s address appearing in the register, a notice stating: 

(i) that a Change of Control Triggering Event has occurred and a Change of Control Offer is being made pursuant to this
Section 2.11 and that all Notes validly tendered will be accepted for payment; 
 (ii) the Change of Control
Purchase Price and the purchase date, which shall be, subject to any contrary requirements of applicable law, a Business Day no earlier than thirty (30) days nor later than sixty (60) days from the date such notice is mailed; 

(iii) the circumstances and relevant facts regarding the Change of Control Triggering Event; and 

(iv) the procedures that Holders of Notes must follow in order to validly tender their Notes (or portions thereof) for
payment and the procedures that Holders of Notes must follow in order to withdraw an election to tender Notes (or portions thereof) for payment. 

  
 10 

 (c) The Company will not be required to make a Change of Control Offer following a Change of
Control Triggering Event if a third party makes the Change of Control Offer in the manner, at the times and otherwise in compliance with the requirements set forth in this Third Supplemental Indenture applicable to a Change of Control Offer made by
the Company and purchases all Notes validly tendered and not withdrawn under such Change of Control Offer. 
 (d) The Company
will comply, to the extent applicable, with the requirements of Section 14(e) of the Exchange Act and any other securities laws or regulations in connection with the repurchase of Notes pursuant to a Change of Control Offer. To the extent that
the provisions of any securities laws or regulations conflict with the provisions of the covenant described above, the Company will comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations
under this covenant by virtue of such compliance. 
 (e) The Company’s obligation to make an offer to repurchase the Notes
as a result of a Change of Control Triggering Event may be waived or modified at any time prior to the occurrence of such Change of Control Triggering Event with the written consent of the holders of a majority in principal amount of the Notes, as
set forth in Article IX of the Base Indenture. 
 Section 2.12. Merger, Consolidation and Sale of Assets.

 (a) For so long as the Notes are outstanding, the Company may not consolidate with or merge into any other corporation or
convey or transfer its properties and assets substantially as an entirety to any Person, unless (i) the successor Person shall be a corporation organized and existing under the laws of the United States (or any State thereof or the District of
Columbia) and shall expressly assume, by a supplemental indenture, the due and punctual payment of the principal of and interest on all the outstanding Notes of such series and the performance of every covenant in this Third Supplemental Indenture
on the part of the Company to be performed or observed, (ii) immediately after giving effect to such transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have
occurred and be continuing, and (iii) the Company shall have delivered to the Trustee an Officer’s Certificate and Opinion of Counsel stating that all conditions precedent set forth in the indenture relating to the consummation of such
consolidation, merger, conveyance or transfer and entering into of such supplemental indenture have been met. In case of any such consolidation, merger conveyance or transfer (other than a lease), such successor corporation will succeed to and be
substituted for the Company as obligor on the Notes of the applicable series, with the same effect as if it had been named in this Third Supplemental Indenture as such obligor. 

(b) For purposes of this Section 2.12, the conveyance or transfer of all the property of one or more Subsidiaries of the Company
which property, if held by the Company instead of such Subsidiaries, would constitute all or substantially all the property of the Company on a consolidated basis, shall be deemed to be the transfer of all or substantially all the property of the
Company. 

  
 11 

 Section 2.13. Events of Default. 

(a) The term “Event of Default” with respect to the Notes shall mean 

(i) default in the payment of the principal of any note issued pursuant to this Third Supplemental Indenture after any
such principal becomes due in accordance with the terms thereof, upon redemption or otherwise; or default in the payment of any interest in respect of such Notes if such default continues for 30 days after any such interest becomes due in accordance
with the terms hereof; 
 (ii) failure to observe or perform any other covenant or agreement contained in the
Notes issued pursuant to this Third Supplemental Indenture, and such failure continuing for 60 days after notice, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in
aggregate principal amount of the outstanding Notes, specifying such failure and requiring it to be remedied and stating that such notice constitutes a notice of default under this Third Supplemental Indenture; 

(iii) failure by the Company or any of its Significant Subsidiaries to pay when due (whether at maturity, upon redemption
or acceleration or otherwise) the principal of any Indebtedness in excess, individually or in the aggregate of US$50 million (or the equivalent thereof in other currencies), if such failure shall continue for more than the period of grace, if any,
applicable thereto and the period for payment has not been expressly extended; 
 (iv) a decree or order by a
court having jurisdiction shall have been entered adjudging the Company or any of its Significant Subsidiaries as bankrupt or insolvent, or approving as properly filed a petition seeking reorganization, concurso mercantil or quiebra of
or by the Company or any of its Significant Subsidiaries and such decree or order shall have continued undischarged or unstayed for a period of 120 days; or a decree or order of a court having jurisdiction for the appointment of a receiver or
liquidator or sindico or conciliador for the liquidation or dissolution of the Company or any of its Significant Subsidiaries, shall have been entered, and such decree or order shall have continued undischarged and unstayed for a
period of 120 days; provided, however, that any Significant Subsidiary may be liquidated or dissolved if, pursuant to such liquidation or dissolution, all or substantially all of its assets are transferred to the Company or another
Significant Subsidiary of the Company; or 
 (v) the Company or any of its Significant Subsidiaries shall
institute any proceeding to be adjudicated as voluntary bankrupt, or shall consent to the filing of a bankruptcy proceeding against it, or shall file a petition or answer or consent seeking reorganization, concurso mercantil or
quiebra, or shall consent to the filing of any such petition, or shall consent to the appointment of a receiver or liquidator or sindico or conciliador or trustee or assignee in bankruptcy or insolvency of it or its property.

 (b) If an Event of Default specified in clause (a)(iv) or (a)(v) above shall occur, the maturity of all outstanding Notes
shall automatically be accelerated and the principal 

  
 12 

 
amount of the Notes, together with accrued interest thereon, shall be immediately due and payable. If any other Event of Default shall occur and be continuing, the Trustee or the Holders of not
less than 25% of the aggregate principal amount of the Notes then outstanding may, by written notice to the Company (and to the Trustee if given by Holders), declare the principal amount of the applicable Notes, together with accrued interest
thereon, immediately due and payable. The right of the Holders to give such acceleration notice shall terminate if the event giving rise to such right shall have been cured before such right is exercised. Any such declaration may be annulled and
rescinded by written notice from the Trustee or the Holders of a majority of the aggregate principal amount of the Notes then outstanding to the Company if all amounts then due with respect to the Notes are paid (other than amount due solely because
of such declaration) and all other defaults with respect to the Notes are cured. 
 (c) Subject to the provisions of the Base
Indenture and this Third Supplemental Indenture relating to the duties of the Trustee, in case the Company shall fail to comply with its obligations under this Third Supplemental Indenture or the Notes and such failure shall be continuing, the
Trustee will be under no obligation to exercise any of its rights or powers under the Third Supplemental Indenture at the request or direction of any of the Holders, unless such Holders shall have offered to the Trustee indemnity reasonably
satisfactory to it. The Holders of a majority in aggregate principal amount of the outstanding Notes will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any
trust or power conferred on the Trustee, to the extent such action does not conflict with the provisions of this Third Supplemental Indenture or applicable law. 
 (d) No Holder of any note will have any right to institute any proceeding with respect to the Third Supplemental Indenture or the Notes or for any remedy thereunder, unless such Holder has previously
given to the Trustee written notice of a continuing Event of Default and unless also the Holders of at least 25% in aggregate principal amount of the outstanding Notes shall have made a written request to the Trustee to institute proceedings in
respect of such Event of Default in its own name as Trustee, such Holder or Holders have offered to the Trustee indemnity reasonably satisfactory to it, the Trustee for 60 days after receipt of such notice has failed to institute any such proceeding
and no direction inconsistent with such request shall have been given to the Trustee during such 60-day period by the Holders of a majority in principal amount of the outstanding Notes. However, such limitations do not apply to a suit individually
instituted by a Holder of a note for enforcement of payment of the principal of, or interest on, such note on or after respective due dates expressed in such note. 
 Section 2.14. Appointment of Agents. The Trustee will initially be the Security Registrar and Paying Agent for the Notes. 

Section 2.15. Defeasance upon Deposit of Moneys or U.S. Government Obligations. 

(a) On the first day after the applicable conditions set forth in Section 12.03 of the Base Indenture have been satisfied, the
Company at any time may terminate (i) all of its obligations under the Notes and this Third Supplemental Indenture (“legal defeasance option”) or (ii) its obligations under Sections 2.9, 2.10, 2.11 and 2.12 of this Third
Supplemental Indenture and, with respect to the Notes only, Section 10.2 of the Base Indenture, and the operation of 

  
 13 

 
Sections 2.13(a)(iii), (iv) and (v) of this Third Supplemental Indenture (but, in the case of Sections 2.13(a)(iv) and (v), with respect only to Significant Subsidiaries)
(“covenant defeasance option”). The Company may exercise its legal defeasance option notwithstanding its prior exercise of its covenant defeasance option. 
 (b) If the Company exercises its legal defeasance option, payment of the Notes may not be accelerated because of an Event of Default with respect to the Notes. If the Company exercises its covenant
defeasance option, payment of the Notes may not be accelerated because of an Event of Default specified in Sections 2.13(a)(ii) (with respect to the covenants identified in clause (a) above), 2.13(a)(iii), 2.13(a)(iv) and 2.13(a)(v) (with
respect only to Significant Subsidiaries in the case of Sections 2.13(a)(iv) and (v)). 
 (c) Notwithstanding clauses (a)
and (b) above, the Company’s obligations with respect to Sections 3.05, 3.06, 3.07, and 12.09 of the Base Indenture, in each case with respect to the Notes only, shall survive until the Notes have been paid in full. 

Section 2.16. Amendments. In addition to the restrictions set forth in Section 14.02 of the Base Indenture, without the
consent or affirmative vote of each Holder of Notes affected thereby, an amendment of this Third Supplemental Indenture or the Base Indenture (with respect to the Notes only) may not reduce the premium payable upon a Change of Control Triggering
Event or, at any time after a Change of Control Triggering Event has occurred, change the time at which the Change of Control Offer relating thereto must be made or at which the Notes must be repurchased pursuant to such Change of Control Offer.

 ARTICLE 3. 
 FORM OF NOTES 
 Section 3.1. Form of Notes. The Notes
and the Trustee’s Certificate of Authentication to be endorsed thereon are to be substantially in the form set forth in Exhibit A. 
 ARTICLE 4. 
 ORIGINAL ISSUE OF NOTES 

Section 4.1. Original Issue of Notes. The Notes may, upon execution of this Third Supplemental Indenture, be executed by the
Company and delivered to the Trustee for authentication, and the Trustee shall, upon Company order, authenticate and deliver such Notes as in such Company order provided. 
 ARTICLE 5. 
 MISCELLANEOUS 

Section 5.1. Ratification of Indenture. The Base Indenture, as supplemented by this Third Supplemental Indenture, is in all
respects ratified and confirmed, and this Third Supplemental Indenture shall be deemed part of the Base Indenture in the manner and to the extent herein and therein provided; provided that the provisions of this Third Supplemental Indenture apply
solely with respect to the Notes. 

  
 14 

 Section 5.2. Trustee Not Responsible for Recitals. The recitals herein contained
are made by the Company and not by the Trustee, and the Trustee assumes no responsibility for the correctness thereof. The Trustee makes no representation as to the validity or sufficiency of this Third Supplemental Indenture. 

Section 5.3. Governing Law. This Third Supplemental Indenture and each Note shall be deemed to be contracts made under the
law of the State of New York, and for all purposes shall be governed by and construed in accordance with such law. 

Section 5.4. Severability. In case any provision in this Indenture or in the Notes shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 Section 5.5. Counterparts. This Third Supplemental Indenture may be executed in any number of counterparts each of which shall be an original; but such counterparts shall together constitute
but one and the same instrument. 
 [Signature pages follow] 

  
 15 

 IN WITNESS WHEREOF, the parties hereto have caused this Third Supplemental Indenture to be
duly executed, all as of the day and year first above written. 
  

			
	 SOUTHERN COPPER CORPORATION,
 as Issuer

		
	By:	 	 /s/ Hans Flury

	Name:	 	Hans A. Flury
	Title:	 	Corporate Assistant Secretary

  
 Signature
Page 
 Third Supplemental Indenture 

 
			
	 WELLS FARGO BANK, NATIONAL ASSOCIATION,
 as Trustee

		
	By:	 	 /s/ Michael Tu

	Name:	 	Michael Tu
	Title:	 	Assistant Vice President

  
 Signature
Page 
 Third Supplemental Indenture 

 EXHIBIT A 
 [FORM OF FACE OF SECURITY] 
 THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING
OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY, WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE AND ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS SECURITY FOR ALL PURPOSES.

 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (55 WATER STREET, NEW
YORK, NEW YORK) (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF DTC (AND ANY PAYMENT HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS
WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
 TRANSFERS OF THIS GLOBAL SECURITY
SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY, OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY, OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A
SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. 

  
 A-1

			
	No. 1	  	 $300,000,000
 As revised by the Schedule of Increases or Decreases
 in Global Security attached
hereto

 3.500% Notes due 2022 
 CUSIP No. 84265V AF2 
 SOUTHERN COPPER CORPORATION, a Delaware corporation
(herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co. or registered assigns, the principal sum of three
hundred million dollars ($300,000,000), as revised by the Schedule of Increases or Decreases in Global Security attached hereto, on November 8, 2022 and to pay interest thereon from November 8, 2012 or from the most recent Interest Payment
Date to which interest has been paid or duly provided for, semi-annually in arrears on May 8 and November 8 of each year, commencing on May 8, 2013 at the rate of 3.500% per annum, until the principal hereof is paid or made
available for payment. Interest on the Securities will accrue from the most recent date to which interest has been paid or, if no interest has been paid, from November 8, 2012. Interest shall be computed on the basis of a 360-day year of twelve
30-day months. 
 The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as
provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the Record Date for such interest, which shall be April 20 or October 20, as
the case may be, next preceding such Interest Payment Date. 
 Additional provisions of this Security are set forth on the other
side of this Security. 
 Unless the certificate of authentication hereon has been executed by the Trustee referred to on the
reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

  
 A-2

 IN WITNESS WHEREOF, the parties have caused this instrument to be duly executed. 

 

			
	SOUTHERN COPPER CORPORATION
		
	By:	 	  

		 	Name:
		 	Title:
		
	By:	 	  

		 	Name:
		 	Title:

  

									
	 TRUSTEE’S CERTIFICATE OF
   AUTHENTICATION
	  		  		  		  	

 This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 

 

			
	Date of Authentication:
	
	  

	
	WELLS FARGO BANK, NATIONAL ASSOCIATION,
	
	 as Trustee, certifies that this is one of the Securities referred to in the Indenture.

		
	by:	 	Authorized Signatory
	
	  

  
 A-3

 [FORM OF REVERSE SIDE OF SECURITY] 

3.500% Notes due 2022 
  

	1.	Indenture. 

 This Security
is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to be issued in one or more series under an Indenture, dated as of April 16, 2010, as supplemented by a Third Supplemental
Indenture, dated November 8, 2012 (as so supplemented, herein called the “Indenture”), between the Company and Wells Fargo Bank, National Association, as Trustee (herein called the “Trustee”, which term includes any
successor trustee under the Indenture), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee
and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount to
$300,000,000. 
 The terms of the Securities include those stated in the Indenture and those made part of the Indenture by
reference to the Trust Indenture Act of 1939 (15 U.S.C. §§ 77aaa-77bbbb) as in effect on the date of the Indenture (the “TIA”). Terms defined in the Indenture and not defined herein have the meanings
ascribed thereto in the Indenture. The Securities are subject to all such terms, and Securityholders are referred to the Indenture and the TIA for a statement of those terms. 

 

	2.	Method of Payment. 

 The
Company will pay interest on the Securities (except defaulted interest) to the Persons who are registered holders of Securities at the close of business on the April 20 or October 20, as the case may be, next preceding the interest payment
date even if Securities are canceled after the record date and on or before the interest payment date. Holders must surrender Securities to a Paying Agent to collect principal payments. The Company will pay principal and interest in money of the
United States of America that at the time of payment is legal tender for payment of public and private debts. Payments in respect of the Securities represented by a Global Security (including principal, premium and interest) will be made by
wire transfer of immediately available funds to the accounts specified by The Depository Trust Company. Payments on the Securities will be made at the office or agency of the Paying Agent and Registrar within the city of Minneapolis, Minnesota
unless the Company elects to make interest payments by check mailed to the Holders at their address set forth in the register. 
  

	3.	Paying Agent and Registrar. 

 Initially, the Trustee will act as Paying Agent and Registrar. The Company may appoint and change any Paying Agent, Registrar or co-registrar without notice. The Company or any of its Subsidiaries may act
as Paying Agent or Registrar. 
  

	4.	Optional Redemption. 

 (a)
Except as described below, the Notes are not redeemable at the Company’s option. The Company is not, however, prohibited from acquiring the Notes by means other than a redemption, whether pursuant to a tender offer, open market purchase or
otherwise, so long as the acquisition does not otherwise violate the terms of the Indenture. 
 (b) The Notes will be
redeemable, at any time and from time to time, in whole or in part, at the Company’s option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest thereon
to, but not including, the date of redemption, and (ii) the sum of the present values of the Remaining Scheduled Payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the applicable redemption date)
discounted to that redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 27.5 basis points. Notwithstanding the foregoing, payments of interest on the Notes will be payable to
the Holders of those Notes registered as such at the close of business on the relevant record dates according to the terms and provisions of the Indenture. In connection with such optional redemption, the following defined terms apply: 

(c) Upon presentation in physical, certificated form of any Note to be redeemed in part only, the Company will execute and the Trustee
will authenticate and deliver to the Company on the order of the holder thereof, at the Company’s expense, a new Note or Notes, of authorized denominations, in principal amount equal to the unredeemed portion of the Note so presented. The
Company may at any time purchase Notes in the open market or otherwise at any price. Any Notes that are redeemed or purchased by the Company shall be delivered to the Trustee for cancellation and may not be reissued or resold. Any redemption and
notice thereof pursuant to the Indenture may, at the Company’s discretion, be subject to the satisfaction of one or more conditions precedent. 

  
 A-4

	5.	Notice of Redemption. 

Notice of any redemption will be mailed at least 30 days but not more than 60 days before the redemption date to each Holder of the Notes
to be redeemed. On and after any redemption date, interest will cease to accrue on the Notes or any portion thereof called for redemption unless the Company defaults in the payment of the redemption price. 

 

	6.	Sinking Fund and Highly Leveraged Transactions. 

 The Securities are not subject to any sinking fund. The Indenture does not include any debt covenants or other provisions which afford holders of the Securities protection in the event of a highly
leveraged transaction. 
  

	7.	Repurchase of Securities at the Option of Holders upon Change of Control Triggering Event. 

Upon a Change of Control Triggering Event, Holders of securities will have the right, subject to certain conditions specified in the
Indenture, to cause the Company to repurchase all or any part of the Securities of such Holder at a purchase price equal to 101% of the principal amount of the Securities to be repurchased plus accrued and unpaid interest, if any, to the date of
purchase (subject to the right of Holders of record on the relevant record date to receive interest due on the relevant interest payment date that is on or prior to the date of purchase) as provided in, and subject to the terms of, the Indenture.

  

	8.	Denominations; Transfer; Exchange. 

 The Securities of this series are issuable only in registered form without coupons in denominations of $2,000 and in integral multiples of $1,000 in excess thereof. As provided in the Indenture and
subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of like tenor of a different authorized denomination, as requested by the Holder surrendering the same.

 As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is
registerable in the security register, upon surrender of this Security for registration of transfer at the Registrar accompanied by a written request for transfer in form satisfactory to the Company and the Registrar duly executed by, the Holder
hereof or his attorney duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or
transferees. 
 No service charge shall be made for any such registration of transfer or exchange, but the Company may require
payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 
  

	9.	Persons Deemed Owners. 

Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or the
Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the
contrary. 

  
 A-5

	10.	Amendment, Waiver. 

 The
Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture
at any time by the Company and the Trustee with the consent of the Holders of a majority in aggregate principal amount of the Securities at the time Outstanding of each series to be affected. The Indenture also contains provisions permitting the
Holders of a majority in aggregate principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and
certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon
the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 
  

	11.	Defaults and Remedies. 

If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this
series may be declared due and payable in the manner and with the effect provided in the Indenture. 
  

	12.	Governing Law. 

 THIS
SECURITY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 
  

	13.	CUSIP Numbers. 

 Pursuant
to a recommendation promulgated by the Committee on Uniform Security Identification Procedures, the Company has caused CUSIP numbers to be printed on the Securities and has directed the Trustee to use CUSIP numbers in notices of redemption as a
convenience to Securityholders. No representation is made as to the accuracy of such numbers either as printed on the Securities or as contained in any notice of redemption and reliance may be placed only on the other identification numbers placed
thereon. 
 The Company will furnish to any Holder of Securities upon written request and without charge to the Holder a copy
of the Indenture which has in it the text of this Security. 

  
 A-6

 SCHEDULE OF INCREASES OR DECREASES IN GLOBAL SECURITY 

The following increases or decreases in this Global Security have been made: 

 

									
	 Date of Exchange
	  	Amount of increase in
Principal Amount of
this Global Security	  	Amount of decrease
in Principal Amount
of this Global
Security	  	Principal Amount of
this Global Security
following each
decrease or increase	  	Signature of
authorized signatory
of Trustee
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  
 A-7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]